Targeted α-emitter therapy of neuroendocrine tumors.
Open accessAbstract
Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, arising from cells of the endocrine system, with various clinical behaviors. Although these neoplasms are considered rare, a significant increase in the incidence and detectability of NET has been noted in many epidemiological studies in recent years. Among the various therapeutic options, peptide receptor radionuclide therapy (PRRT), using somatostatine has been shown to be highly effective and a well-tolerated therapy, improving survival parameters. The current use of radionuclides for PRRT is β-emitters. Due to hypoxia cancer tissue could be resistant for β-emitters. Quite long penetration range had a significant impact on side effects. α-particles with higher energy and shorter penetration range in comparison to β-particles, have distinct advantages for use in targeted therapy. The clinical experience with somatostatine based targeted α therapy (TAT) in NET showed very promising results even in patienicts refractory to treatment with β-emitters. This article summarizes current developments in preclinical and clinical investigation on TAT in NET.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hypoxic cancer tissue could be resistant to beta-emitter treatment, causing radiotherapeutic failure of beta-PRRT.
“Furthermore, hypoxic cancer tissue could be resistant to β-emitter treatment, causing radiotherapeutic failure of β-PRRT (57, 58).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Yao, J. C., Hassan, M. M., Phan, A. T., Dagohoy, C. G., Leary, C. C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510 · see citing works
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,968 · see citing works
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · see citing works
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879 · see citing works
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, É., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard‐Bohas, C., Valle, J. W., Metrakos, P. P., Smith, D. M., Vinik, A. I., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · see citing works
The TNM Classification of Malignant Tumours
Easson, E. C. (1974) · British Journal of Cancer · doi:10.1038/bjc.1974.119 · Cited by 1,006 · see citing works
Zaknun, J. J., Bodei, L., Mueller‐Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O'Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 823 · see citing works
Öberg, K., Knigge, U., Kwekkeboom, D. J., & Perren, A. A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds295 · Cited by 523 · see citing works
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 432 · see citing works
Kwekkeboom, D. J., Bakker, W. H., Kam, B. L. R., Teunissen, J. J. M., Kooij, P. P. M., de Herder, W. W., Feelders, R. A., van Eijck, C. H. J., de Jong, M., Srinivasan, A., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1050-8 · Cited by 426 · see citing works
Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R. A., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 406 · see citing works
Waldherr, C., Pless, M., Maëcke, H. R., Haldemann, A. R., & Mueller‐Brand, J. (2001) · Annals of Oncology · doi:10.1023/a:1011160913619 · Cited by 396 · see citing works
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M. M., Królicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 371 · see citing works
Self-citationRolleman, E., Valkema, R., de Jong, M., Kooij, P., & Krenning, E. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0982-3 · Cited by 321 · see citing works
An overview of targeted alpha therapy
Kim, Y., & Brechbiel, M. W. (2011) · Tumor Biology · doi:10.1007/s13277-011-0286-y · Cited by 280 · see citing works
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., & McCarthy, K. E. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31769 · Cited by 277 · see citing works
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong, M., Breeman, W. A. P., Valkema, R., et al. (2005) · PubMed · Cited by 245 · see citing works
111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial
Virgolini, I. J., Britton, K. E., Buscombe, J. R., Moncayo, R., Paganelli, G., & Riva, P. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31565 · Cited by 243 · see citing works
Kunikowska, J., Królicki, L., Hubalewska–Dydejczyk, A., Mikołajczak, R., Sowa‐Staszczak, A., & Pawlak, D. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1833-x · Cited by 236 · see citing works
Self-citationVillard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K.-T., Mäcke, H. R., Müller‐Brand, J., Rochlitz, C. F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2151 · Cited by 189 · see citing works
Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., & Essler, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4647 · Cited by 155 · see citing works
Baum, R. P., Kulkarni, H. R., Singh, A., Kaemmerer, D., Mueller, D., Prasad, V., Hommann, M., Robiller, F. C., Niepsch, K., Franz, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24524 · Cited by 141 · see citing works
Seregni, E. C., Maccauro, M., Chiesa, C., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2578-5 · Cited by 110 · see citing works
90Y–DOTA– D ‐Phe1–Try3– octreotide in therapy of neuroendocrine malignancies
Paganelli, G., Bodei, L., Handkiewicz-Junak, D., et al. (2002) · Biopolymers · doi:10.1002/bip.10349 · Cited by 106 · see citing works
Norenberg, J. P., Krenning, B. J., Konings, I. R. H. M., Kusewitt, D. F., Nayak, T. K., Anderson, T. L., de Jong, M., Garmestani, K., Brechbiel, M. W., & Kvols, L. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1264 · Cited by 104 · see citing works
Hörsch, D., Ezziddin, S., Haug, A. R., Gratz, K. F., Dunkelmann, S., Miederer, M., Schreckenberger, M., Krause, B. J., Bengel, F. M., Bartenstein, P., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.009 · Cited by 96 · see citing works
Stallons, T. A. R., Saidi, A., Tworowska, I., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1103 · Cited by 74 · see citing works
Nayak, T. K., Norenberg, J. P., Anderson, T. L., Prossnitz, E. R., Stabin, M. G., & Atcher, R. W. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.11.006 · Cited by 73 · see citing works
Kos‐Kudła, B., Blicharz-Dorniak, J., Handkiewicz-Junak, D., Jarząb, B., Jarząb, M., Kunikowska, J., Kuśnierz, K., Król, R., Królicki, L., Krzakowski, M. J., et al. (2014) · Endokrynologia Polska · doi:10.5603/ep.2013.0028 · Cited by 69 · see citing works
Self-citationChan, H. S., Konijnenberg, M., Daniels, T., Nysus, M. V., Makvandi, M., de Blois, E., Breeman, W. A. P., Atcher, R. W., de Jong, M., & Norenberg, J. P. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0240-5 · Cited by 67 · see citing works
Kunikowska, J., Pawlak, D., Bak, M. I., et al. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1163-6 · Cited by 63 · see citing works
Self-citationKos‐Kudła, B., Blicharz-Dorniak, J., Strzelczyk, J., et al. (2017) · Endokrynologia Polska · doi:10.5603/ep.2017.0015 · Cited by 56 · see citing works
Yttrium-labelled peptides for therapy of NET
Bodei, L., Cremonesi, M., Grana, C. M., Chinol, M., Baio, S. M., Severi, S., & Paganelli, G. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2002-y · Cited by 55 · see citing works
Pupillo, G., Boschi, A., Martini, P., Uccelli, L., Pasquali, M., Duatti, A., Domenico, G. D., Giganti, M., Taibi, A., Gambaccini, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3198-z · Cited by 52 · see citing works
Chan, H. S., Konijnenberg, M., de Blois, E., Koelewijn, S. J., Baum, R. P., Morgenstern, A., Bruchertseifer, F., Breeman, W. A. P., & de Jong, M. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0162-2 · Cited by 44 · see citing works
Dumont, R. A., Seiler, D., Marincek, N., Brunner, P., Radojewski, P., Rochlitz, C. F., Müller‐Brand, J., Maëcke, H. R., Briel, M., & Walter, M. A. (2015) · Europe PMC (PubMed Central) · doi:10.7892/boris.67183 · Cited by 29 · see citing works
Heavy ion production of single- and double-strand breaks in plasmid DNA in aqueous solution.
Brons, S., Jakob, B., Taucher-Scholz, G., et al. (2001) · PubMed · Cited by 18 · see citing works
Trofimiuk–Müldner, M., Lewkowicz, E., Wysocka, K., Pach, D., Kiełtyka, A., Stefańska, A., Sowa‐Staszczak, A., Tomaszewska, R., & Hubalewska–Dydejczyk, A. (2017) · Endokrynologia Polska · doi:10.5603/ep.2017.0006 · Cited by 12 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Tworowska I, Delpassand E, Dr. Bolek L, et al: Targeted Alpha-emitter Therapy of Neuroendocrine Tumors using 212 Pb-octreotate (AlphaMe- dix TM) Presented at TAT 11 in 2019. In: Proceedings from the TAT11/ Journal of Medical Imaging and Radiation Sciences, 50:S434, 2019; Ottawa
Cited by
Sorted by citations
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works
- Authors
- Kunikowska, J., & Królicki, L.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Kunikowska, Jolanta
- Venue
- Seminars in Nuclear Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 50
- Issue
- 2
- Pages
- 171-176
- ISSN
- 0001-2998 (ISSN-L)
- OpenAlex
- W3012551003
- Cited by
- 52
- References
- 38
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 12 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 2
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Seminars in Nuclear Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- neuroendocrine tumors, targeted alpha therapy, peptide receptor radionuclide therapy, somatostatin analogues, alpha-emitting radionuclides, tumor hypoxia
- MeSH terms
- Alpha Particles, Animals, Clinical Trials as Topic, Humans, Treatment Outcome, Neuroendocrine Tumors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
